Hospital
Shenandoah Memorial Hospital, INC.
Shenandoah Memorial Hospital, INC. was paid $23.55M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoSHENANDOAH MEMORIAL HOSPITAL, INC.
WOODSTOCK, VA 22664
WOODSTOCK, VA 22664
33aNPI1033166442assigned 05/30/2006
33bProvider typeCritical Access Hospital
28Total paid$23.55M
24GClaims379,385
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Virginia
Rank by total paid#1 of 8
Median peer was paid$893K
This provider vs. median26×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,212 | $970K | |
| 2019 | 42,651 | $2.01M | |
| 2020 | 41,917 | $2.47M | |
| 2021 | 58,027 | $3.62M | |
| 2022 | 65,726 | $4.44M | |
| 2023 | 75,641 | $5.13M | |
| 2024incomplete | 67,211 | $4.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 22,190 | 20,053 | $5.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 11,926 | 10,391 | $3.11M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 6,098 | 5,266 | $2.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 9,630 | 8,667 | $2.40M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 3,652 | 3,411 | $1.42M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.8% | 18,689 | 5,546 | $1.36M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.9% | 13,383 | 4,269 | $911K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 2,495 | 2,363 | $743K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 2,953 | 2,771 | $618K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 7,751 | 7,292 | $598K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.1% | 2,433 | 719 | $486K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 1,939 | 1,477 | $382K |
165 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 976 | $370K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 7,304 | $350K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,622 | $320K |
| 97161 | <1% | 1,107 | $215K | |
| 97162 | <1% | 853 | $183K | |
| 87428 | <1% | 6,740 | $146K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 19,808 | $145K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 318 | $142K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,645 | $123K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,867 | $123K |
| 80053 | Comprehensive metabolic panel | <1% | 17,635 | $111K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 320 | $107K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,136 | $83K |
| G0378 | Hospital observation service, per hour | <1% | 275 | $78K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,290 | $68K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 500 | $61K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 102 | $56K |
| 73564 | <1% | 1,409 | $51K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 603 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,244 | $49K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,779 | $47K |
| 73110 | <1% | 1,006 | $41K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,154 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,514 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,852 | $35K |
| 73610 | <1% | 1,046 | $35K | |
| 73030 | <1% | 981 | $34K | |
| 76830 | Ultrasound, transvaginal | <1% | 197 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 221 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,667 | $32K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,137 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,583 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,628 | $28K |
| 73630 | <1% | 1,012 | $26K | |
| 80061 | Lipid panel | <1% | 2,055 | $25K |
| 73130 | <1% | 966 | $24K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 425 | $22K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 59 | $20K |
| 81025 | <1% | 4,093 | $16K | |
| 85379 | <1% | 2,298 | $16K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 83 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,774 | $15K |
| 87420 | <1% | 676 | $14K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 385 | $14K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,424 | $14K |
| 87807 | <1% | 1,765 | $13K | |
| 73502 | <1% | 309 | $13K | |
| 81002 | <1% | 3,929 | $13K | |
| 83880 | <1% | 792 | $10K | |
| 87040 | <1% | 1,098 | $9K | |
| 85610 | <1% | 2,703 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 219 | $9K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,179 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 29 | $8K |
| 81003 | <1% | 5,418 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 192 | $7K |
| 72110 | <1% | 111 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $7K |
| 72100 | <1% | 138 | $6K | |
| 80143 | <1% | 1,020 | $6K | |
| 97163 | <1% | 71 | $6K | |
| 84484 | <1% | 5,182 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,585 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 294 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,003 | $5K |
| 87634 | <1% | 306 | $5K | |
| 73562 | <1% | 84 | $5K | |
| 97165 | <1% | 12 | $5K | |
| 92523 | <1% | 13 | $5K | |
| 76536 | <1% | 25 | $4K | |
| 80306 | <1% | 2,668 | $4K | |
| J3490 | Unclassified drugs | <1% | 4,284 | $4K |
| 12001 | <1% | 12 | $3K | |
| 87081 | <1% | 5,541 | $3K | |
| 86140 | <1% | 1,100 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,367 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 306 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 36 | $3K |
| 80179 | <1% | 945 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,516 | $3K |
| 90715 | <1% | 84 | $2K | |
| 81001 | <1% | 8,883 | $2K | |
| 82947 | <1% | 460 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,676 | $2K |
| 72131 | <1% | 16 | $2K | |
| 96376 | <1% | 1,806 | $2K | |
| 84466 | <1% | 184 | $2K | |
| 85652 | <1% | 640 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,813 | $2K |
| 87400 | <1% | 208 | $2K | |
| 74018 | <1% | 58 | $2K | |
| 97750 | <1% | 43 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 223 | $2K |
| 84703 | <1% | 3,227 | $2K | |
| 83690 | <1% | 4,499 | $1K | |
| 83540 | <1% | 202 | $1K | |
| 85018 | <1% | 177 | $1K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 670 | $1K |
| 83735 | <1% | 1,089 | $1K | |
| 73140 | <1% | 41 | $999.22 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,696 | $980.33 |
| 87186 | <1% | 1,495 | $937.73 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,263 | $916.72 |
| 84145 | <1% | 196 | $850.88 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 26 | $801.90 |
| 82607 | <1% | 67 | $692.42 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 716 | $634.55 |
| 87070 | <1% | 480 | $625.21 | |
| 76801 | <1% | 13 | $624.56 | |
| 83605 | <1% | 1,480 | $588.36 | |
| 87077 | <1% | 824 | $486.33 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 82 | $470.01 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $444.42 |
| 73620 | <1% | 27 | $428.48 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,627 | $410.39 |
| 73080 | <1% | 13 | $400.14 | |
| 80076 | <1% | 162 | $352.70 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 82 | $346.70 |
| 94664 | <1% | 707 | $325.79 | |
| 73090 | <1% | 27 | $320.98 | |
| 84439 | <1% | 43 | $293.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,711 | $293.08 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,242 | $242.46 |
| 82948 | <1% | 1,235 | $237.63 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 263 | $232.86 |
| 80047 | <1% | 165 | $223.98 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 297 | $217.81 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 386 | $217.46 |
| 83655 | <1% | 12 | $216.83 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,367 | $210.55 |
| 74019 | <1% | 13 | $208.92 | |
| 85730 | <1% | 258 | $187.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,087 | $185.05 |
| 85014 | <1% | 63 | $173.32 | |
| 82746 | <1% | 13 | $158.10 | |
| 87205 | <1% | 244 | $130.52 | |
| 74022 | <1% | 18 | $99.49 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $92.81 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 905 | $91.93 |
| 87088 | <1% | 59 | $91.08 | |
| 82270 | <1% | 28 | $73.65 | |
| 94760 | <1% | 343 | $58.31 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 151 | $50.40 |
| 82550 | <1% | 67 | $45.14 | |
| 85027 | <1% | 15 | $44.53 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 850 | $39.28 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 192 | $35.80 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 167 | $24.75 |
| 84702 | <1% | 29 | $20.02 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 41 | $8.05 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 89 | $5.46 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 253 | $2.25 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 116 | $0.32 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 17 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 28 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 126 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 29 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 45 | $0.00 |
| 73600 | 0% | 14 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 29 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 49 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 44 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 70 | $0.00 |
| 29125 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHEATER, FLOYD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Shenandoah Memorial Hospital | Woodstock, VA | $2.07M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.